FW: [HepC] Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, July 03, 2000 11:48 PMHepCegroupsSubject: [HepC] Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Treatment of Hepatitis C InfectionCAMBRIDGE, Mass., July 3 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that patient dosing is underway in a Phase II clinical trial of VX-497, a novel drug for the treatment of hepatitis C virus (HCV) infection, in combination with interferon alpha. HCV infection is a chronic viral disease affecting 2.7 million people in the United States. HCV causes inflammation of the liver, which may lead to cirrhosis, liver failure, and liver cancer. The trial announced today follows the completion of a clinical study assessing the safety and preliminary efficacy of VX-497 as monotherapy for treatment of HCV infection.(Photo: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO ) "In our in vitro studies against a panel of viruses closely related to HCV, VX-497 and interferon alpha exhibited potent additive activity. This is our first opportunity to assess the activity of VX-497 plus interferon-alpha dosed in combination for HCV patients. Our goal is to assess whether this combination can provide benefit to HCV patients," said Dr. Vicki Sato, Senior Vice President of Research and Development and Chief Scientific Officer of Vertex. "With the information we gain from this and other clinical studies, we intend to initiate pivotal studies of VX-497 in HCV in 2001."Hepatitis C virus infection is recognized as a major threat to public health. Approximately 2.7 million people in the United States are chronically infected with the hepatitis C virus, although many are currently undiagnosed. According to the Centers for Disease Control (CDC), hospitalization and death rates due to HCV are projected to triple from current levels over the next 10- 15 years.Background on VX-497 Clinical Trials and IMPDH Mechanism of Action The study of VX-497 in combination with interferon-alpha announced today is a randomized, double-blind, placebo-controlled dose-escalation Phase II trial which will enroll up to 54 adult HCV patients who have not previously received HCV antiviral therapy. Patients will receive VX-497 plus interferon-alpha, or placebo plus interferon-alpha, for four weeks. The trial will assess the safety and pharmacokinetics of VX-497 when administered in combination with interferon-alpha. The trial will also assess antiviral activity of treatment based on changes in HCV viral RNA and changes in levels of serum alanine aminotransferase (ALT), a marker of liver inflammation. The objective of the study will be to compare the rate of viral decline in patients treated with the combination of VX-497 and interferon alpha to that in patients treated with interferon alpha alone. The trial will be conducted at centers in the United States.At a medical conference in late 1999, Vertex presented results from a Phase II 28-day study of VX-497 as monotherapy in HCV patients non-responsive to prior treatment with interferon-alpha, which suggest that the drug was well-tolerated and resulted in reduced ALT levels. This monotherapy study was extended for three months to further assess the safety and pharmacokinetics of VX-497 for a longer treatment duration.Based on clinical results and an analysis of patient need, Vertex is focusing its resources on developing VX-497, an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMPDH), for the treatment of HCV. The Company has also evaluated VX-497 for the treatment of psoriasis, and results from a Phase II psoriasis trial support the therapeutic potential of IMPDH inhibitors for treating autoimmune diseases. In early 2000, Vertex selected a distinct IMPDH inhibitor, VX-148, as its lead drug development candidate for the treatment of autoimmune diseases, and has begun preclinical studies with the compound. If preclinical studies are successful, the Company could begin clinical trials of VX-148 in 2001.VX-497 and VX-148 are potent inhibitors of inosine monophosphate dehydrogenase (IMPDH), a cellular enzyme that is essential for production of guanine nucleotides, one of the building blocks of RNA and DNA. Blocking IMPDH may be an effective strategy for blocking the proliferation (growth) of certain cell types, such as lymphocytes, and the replication of viruses, since both lymphocytes and viruses depend on nucleotide synthesis for replication.Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. The Company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary approach, information-based drug design, that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. Vertex's first approved product is Agenerase (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome.There can be no assurance that clinical trials of VX-497 will continue, that initial VX-497 clinical trial results will be predictive of any future results, that VX-497 will be the subject of filings for regulatory approval, that VX-497 will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that VX-497 will be marketed successfully. There can be no assurance that preclinical trials of VX-148 will continue, or that Vertex will initiate clinical studies of VX-148. Investors are also directed to consider other risks and uncertainties discussed in Vertex documents filed with the Securities and Exchange Commission.Vertex's press releases are also available at www.vpharm.com or by fax-on-demand at (800) 758-5804 - Code: 938395SOURCE Vertex Pharmaceuticals Incorporated ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~In honor of the Fourth of July, Butterbean's Place is featuringexciting books, music and movies that are sure to entertain. Take alook at <A HREF="http://www.vstore.com/cgi-bin/pagegen/homestead-vstore/5365838/page.html?mode=home & file=/page/home/home.spl">http://5365838.homestead-vstore.com</A> now.Hurry, these products are available while supplies last!Send your comments to HepC-owneronelist Subscribe: HepC-subscribeonelist Unsubscribe: HepC-unsubscribeonelist To subscribe to any of my other Mailing Lists (HOOTS Clean Joke List, Southern Heritage, Freight Haulers, Freedom Watch, Christian Activist)contact me at: demastus@...HAVE YOUR OWN 800# - HOME OR BUSINESSONLY 6.9 cents per minute! - Six second billing NO SET-UP FEES - NO MONTHLY FEES - NO SURCHARGESSAME RATE FOR LONG DISTANCE CALLS FROM HOME!FOR SERVICE 1-800-360-8918 - RD# 205Get paid to surf the web:http://www.alladvantage.com/go.asp?refid=FVG-196NOTICE: In accordance with Title 17 U.S.C. Section 107, this material is distributed, without profit, for research or educational purposes to those who have expressed a prior interest.

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, July 03, 2000 11:48 PMHepCegroupsSubject: [HepC] Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Treatment of Hepatitis C InfectionCAMBRIDGE, Mass., July 3 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that patient dosing is underway in a Phase II clinical trial of VX-497, a novel drug for the treatment of hepatitis C virus (HCV) infection, in combination with interferon alpha. HCV infection is a chronic viral disease affecting 2.7 million people in the United States. HCV causes inflammation of the liver, which may lead to cirrhosis, liver failure, and liver cancer. The trial announced today follows the completion of a clinical study assessing the safety and preliminary efficacy of VX-497 as monotherapy for treatment of HCV infection.(Photo: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO ) "In our in vitro studies against a panel of viruses closely related to HCV, VX-497 and interferon alpha exhibited potent additive activity. This is our first opportunity to assess the activity of VX-497 plus interferon-alpha dosed in combination for HCV patients. Our goal is to assess whether this combination can provide benefit to HCV patients," said Dr. Vicki Sato, Senior Vice President of Research and Development and Chief Scientific Officer of Vertex. "With the information we gain from this and other clinical studies, we intend to initiate pivotal studies of VX-497 in HCV in 2001."Hepatitis C virus infection is recognized as a major threat to public health. Approximately 2.7 million people in the United States are chronically infected with the hepatitis C virus, although many are currently undiagnosed. According to the Centers for Disease Control (CDC), hospitalization and death rates due to HCV are projected to triple from current levels over the next 10- 15 years.Background on VX-497 Clinical Trials and IMPDH Mechanism of Action The study of VX-497 in combination with interferon-alpha announced today is a randomized, double-blind, placebo-controlled dose-escalation Phase II trial which will enroll up to 54 adult HCV patients who have not previously received HCV antiviral therapy. Patients will receive VX-497 plus interferon-alpha, or placebo plus interferon-alpha, for four weeks. The trial will assess the safety and pharmacokinetics of VX-497 when administered in combination with interferon-alpha. The trial will also assess antiviral activity of treatment based on changes in HCV viral RNA and changes in levels of serum alanine aminotransferase (ALT), a marker of liver inflammation. The objective of the study will be to compare the rate of viral decline in patients treated with the combination of VX-497 and interferon alpha to that in patients treated with interferon alpha alone. The trial will be conducted at centers in the United States.At a medical conference in late 1999, Vertex presented results from a Phase II 28-day study of VX-497 as monotherapy in HCV patients non-responsive to prior treatment with interferon-alpha, which suggest that the drug was well-tolerated and resulted in reduced ALT levels. This monotherapy study was extended for three months to further assess the safety and pharmacokinetics of VX-497 for a longer treatment duration.Based on clinical results and an analysis of patient need, Vertex is focusing its resources on developing VX-497, an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMPDH), for the treatment of HCV. The Company has also evaluated VX-497 for the treatment of psoriasis, and results from a Phase II psoriasis trial support the therapeutic potential of IMPDH inhibitors for treating autoimmune diseases. In early 2000, Vertex selected a distinct IMPDH inhibitor, VX-148, as its lead drug development candidate for the treatment of autoimmune diseases, and has begun preclinical studies with the compound. If preclinical studies are successful, the Company could begin clinical trials of VX-148 in 2001.VX-497 and VX-148 are potent inhibitors of inosine monophosphate dehydrogenase (IMPDH), a cellular enzyme that is essential for production of guanine nucleotides, one of the building blocks of RNA and DNA. Blocking IMPDH may be an effective strategy for blocking the proliferation (growth) of certain cell types, such as lymphocytes, and the replication of viruses, since both lymphocytes and viruses depend on nucleotide synthesis for replication.Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. The Company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary approach, information-based drug design, that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. Vertex's first approved product is Agenerase (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome.There can be no assurance that clinical trials of VX-497 will continue, that initial VX-497 clinical trial results will be predictive of any future results, that VX-497 will be the subject of filings for regulatory approval, that VX-497 will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that VX-497 will be marketed successfully. There can be no assurance that preclinical trials of VX-148 will continue, or that Vertex will initiate clinical studies of VX-148. Investors are also directed to consider other risks and uncertainties discussed in Vertex documents filed with the Securities and Exchange Commission.Vertex's press releases are also available at www.vpharm.com or by fax-on-demand at (800) 758-5804 - Code: 938395SOURCE Vertex Pharmaceuticals Incorporated ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~In honor of the Fourth of July, Butterbean's Place is featuringexciting books, music and movies that are sure to entertain. Take alook at <A HREF="http://www.vstore.com/cgi-bin/pagegen/homestead-vstore/5365838/page.html?mode=home & file=/page/home/home.spl">http://5365838.homestead-vstore.com</A> now.Hurry, these products are available while supplies last!Send your comments to HepC-owneronelist Subscribe: HepC-subscribeonelist Unsubscribe: HepC-unsubscribeonelist To subscribe to any of my other Mailing Lists (HOOTS Clean Joke List, Southern Heritage, Freight Haulers, Freedom Watch, Christian Activist)contact me at: demastus@...HAVE YOUR OWN 800# - HOME OR BUSINESSONLY 6.9 cents per minute! - Six second billing NO SET-UP FEES - NO MONTHLY FEES - NO SURCHARGESSAME RATE FOR LONG DISTANCE CALLS FROM HOME!FOR SERVICE 1-800-360-8918 - RD# 205Get paid to surf the web:http://www.alladvantage.com/go.asp?refid=FVG-196NOTICE: In accordance with Title 17 U.S.C. Section 107, this material is distributed, without profit, for research or educational purposes to those who have expressed a prior interest.

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, July 03, 2000 11:48 PMHepCegroupsSubject: [HepC] Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Treatment of Hepatitis C InfectionCAMBRIDGE, Mass., July 3 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that patient dosing is underway in a Phase II clinical trial of VX-497, a novel drug for the treatment of hepatitis C virus (HCV) infection, in combination with interferon alpha. HCV infection is a chronic viral disease affecting 2.7 million people in the United States. HCV causes inflammation of the liver, which may lead to cirrhosis, liver failure, and liver cancer. The trial announced today follows the completion of a clinical study assessing the safety and preliminary efficacy of VX-497 as monotherapy for treatment of HCV infection.(Photo: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO ) "In our in vitro studies against a panel of viruses closely related to HCV, VX-497 and interferon alpha exhibited potent additive activity. This is our first opportunity to assess the activity of VX-497 plus interferon-alpha dosed in combination for HCV patients. Our goal is to assess whether this combination can provide benefit to HCV patients," said Dr. Vicki Sato, Senior Vice President of Research and Development and Chief Scientific Officer of Vertex. "With the information we gain from this and other clinical studies, we intend to initiate pivotal studies of VX-497 in HCV in 2001."Hepatitis C virus infection is recognized as a major threat to public health. Approximately 2.7 million people in the United States are chronically infected with the hepatitis C virus, although many are currently undiagnosed. According to the Centers for Disease Control (CDC), hospitalization and death rates due to HCV are projected to triple from current levels over the next 10- 15 years.Background on VX-497 Clinical Trials and IMPDH Mechanism of Action The study of VX-497 in combination with interferon-alpha announced today is a randomized, double-blind, placebo-controlled dose-escalation Phase II trial which will enroll up to 54 adult HCV patients who have not previously received HCV antiviral therapy. Patients will receive VX-497 plus interferon-alpha, or placebo plus interferon-alpha, for four weeks. The trial will assess the safety and pharmacokinetics of VX-497 when administered in combination with interferon-alpha. The trial will also assess antiviral activity of treatment based on changes in HCV viral RNA and changes in levels of serum alanine aminotransferase (ALT), a marker of liver inflammation. The objective of the study will be to compare the rate of viral decline in patients treated with the combination of VX-497 and interferon alpha to that in patients treated with interferon alpha alone. The trial will be conducted at centers in the United States.At a medical conference in late 1999, Vertex presented results from a Phase II 28-day study of VX-497 as monotherapy in HCV patients non-responsive to prior treatment with interferon-alpha, which suggest that the drug was well-tolerated and resulted in reduced ALT levels. This monotherapy study was extended for three months to further assess the safety and pharmacokinetics of VX-497 for a longer treatment duration.Based on clinical results and an analysis of patient need, Vertex is focusing its resources on developing VX-497, an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMPDH), for the treatment of HCV. The Company has also evaluated VX-497 for the treatment of psoriasis, and results from a Phase II psoriasis trial support the therapeutic potential of IMPDH inhibitors for treating autoimmune diseases. In early 2000, Vertex selected a distinct IMPDH inhibitor, VX-148, as its lead drug development candidate for the treatment of autoimmune diseases, and has begun preclinical studies with the compound. If preclinical studies are successful, the Company could begin clinical trials of VX-148 in 2001.VX-497 and VX-148 are potent inhibitors of inosine monophosphate dehydrogenase (IMPDH), a cellular enzyme that is essential for production of guanine nucleotides, one of the building blocks of RNA and DNA. Blocking IMPDH may be an effective strategy for blocking the proliferation (growth) of certain cell types, such as lymphocytes, and the replication of viruses, since both lymphocytes and viruses depend on nucleotide synthesis for replication.Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. The Company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary approach, information-based drug design, that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. Vertex's first approved product is Agenerase (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome.There can be no assurance that clinical trials of VX-497 will continue, that initial VX-497 clinical trial results will be predictive of any future results, that VX-497 will be the subject of filings for regulatory approval, that VX-497 will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that VX-497 will be marketed successfully. There can be no assurance that preclinical trials of VX-148 will continue, or that Vertex will initiate clinical studies of VX-148. Investors are also directed to consider other risks and uncertainties discussed in Vertex documents filed with the Securities and Exchange Commission.Vertex's press releases are also available at www.vpharm.com or by fax-on-demand at (800) 758-5804 - Code: 938395SOURCE Vertex Pharmaceuticals Incorporated ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~In honor of the Fourth of July, Butterbean's Place is featuringexciting books, music and movies that are sure to entertain. Take alook at <A HREF="http://www.vstore.com/cgi-bin/pagegen/homestead-vstore/5365838/page.html?mode=home & file=/page/home/home.spl">http://5365838.homestead-vstore.com</A> now.Hurry, these products are available while supplies last!Send your comments to HepC-owneronelist Subscribe: HepC-subscribeonelist Unsubscribe: HepC-unsubscribeonelist To subscribe to any of my other Mailing Lists (HOOTS Clean Joke List, Southern Heritage, Freight Haulers, Freedom Watch, Christian Activist)contact me at: demastus@...HAVE YOUR OWN 800# - HOME OR BUSINESSONLY 6.9 cents per minute! - Six second billing NO SET-UP FEES - NO MONTHLY FEES - NO SURCHARGESSAME RATE FOR LONG DISTANCE CALLS FROM HOME!FOR SERVICE 1-800-360-8918 - RD# 205Get paid to surf the web:http://www.alladvantage.com/go.asp?refid=FVG-196NOTICE: In accordance with Title 17 U.S.C. Section 107, this material is distributed, without profit, for research or educational purposes to those who have expressed a prior interest.

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, July 03, 2000 11:48 PMHepCegroupsSubject: [HepC] Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Treatment of Hepatitis C InfectionCAMBRIDGE, Mass., July 3 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that patient dosing is underway in a Phase II clinical trial of VX-497, a novel drug for the treatment of hepatitis C virus (HCV) infection, in combination with interferon alpha. HCV infection is a chronic viral disease affecting 2.7 million people in the United States. HCV causes inflammation of the liver, which may lead to cirrhosis, liver failure, and liver cancer. The trial announced today follows the completion of a clinical study assessing the safety and preliminary efficacy of VX-497 as monotherapy for treatment of HCV infection.(Photo: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO ) "In our in vitro studies against a panel of viruses closely related to HCV, VX-497 and interferon alpha exhibited potent additive activity. This is our first opportunity to assess the activity of VX-497 plus interferon-alpha dosed in combination for HCV patients. Our goal is to assess whether this combination can provide benefit to HCV patients," said Dr. Vicki Sato, Senior Vice President of Research and Development and Chief Scientific Officer of Vertex. "With the information we gain from this and other clinical studies, we intend to initiate pivotal studies of VX-497 in HCV in 2001."Hepatitis C virus infection is recognized as a major threat to public health. Approximately 2.7 million people in the United States are chronically infected with the hepatitis C virus, although many are currently undiagnosed. According to the Centers for Disease Control (CDC), hospitalization and death rates due to HCV are projected to triple from current levels over the next 10- 15 years.Background on VX-497 Clinical Trials and IMPDH Mechanism of Action The study of VX-497 in combination with interferon-alpha announced today is a randomized, double-blind, placebo-controlled dose-escalation Phase II trial which will enroll up to 54 adult HCV patients who have not previously received HCV antiviral therapy. Patients will receive VX-497 plus interferon-alpha, or placebo plus interferon-alpha, for four weeks. The trial will assess the safety and pharmacokinetics of VX-497 when administered in combination with interferon-alpha. The trial will also assess antiviral activity of treatment based on changes in HCV viral RNA and changes in levels of serum alanine aminotransferase (ALT), a marker of liver inflammation. The objective of the study will be to compare the rate of viral decline in patients treated with the combination of VX-497 and interferon alpha to that in patients treated with interferon alpha alone. The trial will be conducted at centers in the United States.At a medical conference in late 1999, Vertex presented results from a Phase II 28-day study of VX-497 as monotherapy in HCV patients non-responsive to prior treatment with interferon-alpha, which suggest that the drug was well-tolerated and resulted in reduced ALT levels. This monotherapy study was extended for three months to further assess the safety and pharmacokinetics of VX-497 for a longer treatment duration.Based on clinical results and an analysis of patient need, Vertex is focusing its resources on developing VX-497, an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMPDH), for the treatment of HCV. The Company has also evaluated VX-497 for the treatment of psoriasis, and results from a Phase II psoriasis trial support the therapeutic potential of IMPDH inhibitors for treating autoimmune diseases. In early 2000, Vertex selected a distinct IMPDH inhibitor, VX-148, as its lead drug development candidate for the treatment of autoimmune diseases, and has begun preclinical studies with the compound. If preclinical studies are successful, the Company could begin clinical trials of VX-148 in 2001.VX-497 and VX-148 are potent inhibitors of inosine monophosphate dehydrogenase (IMPDH), a cellular enzyme that is essential for production of guanine nucleotides, one of the building blocks of RNA and DNA. Blocking IMPDH may be an effective strategy for blocking the proliferation (growth) of certain cell types, such as lymphocytes, and the replication of viruses, since both lymphocytes and viruses depend on nucleotide synthesis for replication.Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. The Company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary approach, information-based drug design, that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. Vertex's first approved product is Agenerase (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome.There can be no assurance that clinical trials of VX-497 will continue, that initial VX-497 clinical trial results will be predictive of any future results, that VX-497 will be the subject of filings for regulatory approval, that VX-497 will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that VX-497 will be marketed successfully. There can be no assurance that preclinical trials of VX-148 will continue, or that Vertex will initiate clinical studies of VX-148. Investors are also directed to consider other risks and uncertainties discussed in Vertex documents filed with the Securities and Exchange Commission.Vertex's press releases are also available at www.vpharm.com or by fax-on-demand at (800) 758-5804 - Code: 938395SOURCE Vertex Pharmaceuticals Incorporated ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~In honor of the Fourth of July, Butterbean's Place is featuringexciting books, music and movies that are sure to entertain. Take alook at <A HREF="http://www.vstore.com/cgi-bin/pagegen/homestead-vstore/5365838/page.html?mode=home & file=/page/home/home.spl">http://5365838.homestead-vstore.com</A> now.Hurry, these products are available while supplies last!Send your comments to HepC-owneronelist Subscribe: HepC-subscribeonelist Unsubscribe: HepC-unsubscribeonelist To subscribe to any of my other Mailing Lists (HOOTS Clean Joke List, Southern Heritage, Freight Haulers, Freedom Watch, Christian Activist)contact me at: demastus@...HAVE YOUR OWN 800# - HOME OR BUSINESSONLY 6.9 cents per minute! - Six second billing NO SET-UP FEES - NO MONTHLY FEES - NO SURCHARGESSAME RATE FOR LONG DISTANCE CALLS FROM HOME!FOR SERVICE 1-800-360-8918 - RD# 205Get paid to surf the web:http://www.alladvantage.com/go.asp?refid=FVG-196NOTICE: In accordance with Title 17 U.S.C. Section 107, this material is distributed, without profit, for research or educational purposes to those who have expressed a prior interest.